Member Info for rebarm

PR. That's what he said. Yesterday's RNS clarifies how funding will be made available now. IMO, it represents a positive step for FDBK as funding approval deliverables can be readily linked to Bleepa - cost savings and reduced waiting lists.

Too many folks on this BB and, no doubt others, blaming TO for slow progress. Perhaps greater consideration of the impact of a dysfunctional NHS on any/all decision making might help!

I've written to TO and suggested he gives a wider audience the benefit of this webinar.

Another idea PR and V, have you tried opening an account on HSJ? That was necessary to access the webinar. I would put a link to my account on here but it has all my personal info - name, email, phone!!

Mind you, if you do eventually manage to access the response may well be, "what a waste of time!!"

PR, yes, it was confirmed.

I was late on the call but got the full TO pitch. He has often comes across to me as being rather light weight with that irritating half smile which borders on the smug. However, yesterday was by far the best delivery I've seen. Serious throughout and content rich. He talked about how the erf uncapping could help the roll-out of technology, will reduce waiting times and lists, reduce costs and integrate expertise. Worth tracking down just for his set.

One thing that the call did reinforce for me, which has been a long standing concern I have about the NHS, is the amount of money that is wasted through the ICS's need for independence. Unnecessary replication of evaluation and decision making adds to NHS costs and timescales. The work that is being done at Sussex could easily be rolled out across the country but, no, each individual ICS is undoubtedly going through the same long-drawn out process. IMO, it's criminal!!

Totally agree Vascular. IMC is an excellent platform. I suspect the problem with HSJ is that it has come from the practitioner's side rather than FDBK hence the somewhat amateurish approach.

Try app.swapcard.com and either logon if you have an account or open one. I am still able to access so assume it will be readily available. Certainly worth a watch/listen to hear the benefits from the user's perspective.

Today's presentation was excellent! You have no excuses for not joining. The link was posted on this BB a couple of days ago and connection was straightforward. I believe it is still available on the HSJ website.

FYI, 3 presenters. Clinical SRO for Diagnostics & CDC Programme at Sussex ICS; GP & senior partner at practice using system and TO. The first two did the bulk of the presenting/talking. All very positive and confirmed, from a practitioner's standpoint, benefits of Bleepa. TO's contribution first class!

Suggest you attempt to check it out before criticising!

FYI, 11:48:18 is a buy. This year's ISA!

Thanks for the City AM link Bill. However, gentle warning all.

Panmure Liberum is FDBK's NOMAD and Walbrook is their PR agent. Far be it from me to suggest they might be biased!

However, if the Govt's plan shows positive signs then we're off to the races!!

Thanks mol

An excellent, informative interview and great exposure for Opti.

A very well constructed model for a booming market and an excellent platform for Slimbiome. If Dr Morepen deliver on the numbers, then Opti will clearly benefit.

Is there a glimmer of light at the end of what has been a long and gloomy tunnel!

Mol42, keep up the good work. It's appreciated by many

Adyan, suggest you check RNS 30th., April 'Manufacturing agreement with KAG Industries'. May allay some of your concerns!

Wildbunch........well said. Too many doomsters on this board!

Don't let the MMs mess around with you. 9:33:55 @ 1.945 was a buy!

Couple of good posts Dibs. Like you I'm a disappointed LTH with FDBK parked at the back of the bottom drawer. Maybe time to shake off the dust and add.

However, having read and reread the RNS, despite what seems very positive news I do I have a few concerns:

1. CEO - if this targeted funding is as positive as he suggests why hasn't TO been out shouting from the rooftops? No interviews today and none scheduled with the likes of IMC. I'm sure he's exceptionally busy but this needs promotion. As we all know, TO is prone to waffle and this lengthy RNS while bursting with good news is also peppered with shoulds, coulds, maybes and mights! Sensible backside covering, yes, but does raise a ? or two with me

2. ERF widens the availability of funds for different projects, it is not solely for areas that are targeted by FDBK so inevitably given staff shortages in the NHS it will slow down decision making and award of contracts even with an excellent delivery partner in place

3. Competition - has Bleepa now been identified as the sole DEAG solution? I don't believe so in which case competition must impact timescales

4. NHS - each Region has its own jealously guarded set of processes and people to manage them. For example, the multiple, long term trails that FDBK have been running are largely thanks to Regions wanting to prove their worth by doing their own thing. It's one of the major reasons why the NHS is in such a mess - unnecessary duplication of processes and functions. I'm not certain that this will disappear overnight

However, switching on the positive, we've been waiting too long for news like this and if FDBK can deliver even a fraction of what the RNS is suggesting then it's certainly top-up time, big time.

Mad, approximately 11%

I think the decimal point is in the wrong place!!!

C'mon Elrico, you can do much better than that. Muckle is some 2-bit law firm in Newcastle with a partner that worked on the Dermatonics acquisition. All very close to (SBTX) home don't you think?

Until such time as names and timescales can be pinned to these so called multinational/partner 'discussions' this is nothing more than the same old, same old SOH waffle. It's the norm with many AIM companies wanting to keep investors onside but, in reality, have nothing to show for it

Oh dear, SOH. Poor judgement perhaps?

Is that really the case! Every day the media has got some story about mental health, a lot of which, if for real, will be stress related. Most sufferers appear to be from younger generations many, I suspect, mimicking what they see on social media so a supplement targeting this sector might have some commercial mileage